Article

Preliminary Study of a New Cholecystographic Medium

Author and Disclosure Information

Abstract

EXPERIMENTAL studies1 recently have resulted in the preparation of a new organic iodine compound, 3-(3-amino-2, 4, 6-triiodophenyl)-2-ethylpropanoic acid (Telepaque*) for cholecystography. On the basis of animal experimentation2,3,4 this compound compared favorably with iodoalphionic acid (Priodax) from the viewpoint of both toxicity and gallbladder concentration. In view of the high percentage of side effects encountered with Priodax, particularly nausea and diarrhea, clinical trial of this new medium appeared justified. The following preliminary report embodies the results obtained regarding both gallbladder visualization and side effects in a series of 232 unselected cases, half of whom received Priodax and half Telepaque.

Telepaque is a cream-colored solid, containing 66.68 per cent iodine by weight, in organic combination (compared with 51.38 per cent in Priodax). It is insoluble in water, and soluble in dilute alkali and various organic solvents. Hoppe,2 in experiments on dogs and cats, showed that the gallbladder visualization obtained with Telepaque compared favorably with that produced by Priodax. His studies on dogs revealed that 500 mg./Kg. of Telepaque effected as dense a gallbladder shadow as 1,000 mg./Kg. of Priodax. Acute intravenous toxicity studies in mice2 showed Telepaque to be slightly more toxic than Priodax. However, on oral administration, the former proved to be less than one-third as toxic. Tolerance studies in dogs following repeated massive oral doses of Telepaque have been reported by Hoppe,2 McAuliff and McChesney3 and Goble.4 Renal and hepatic function tests, as well as gross and microscopic tissue studies, showed no evidence of pathologic change attributable either to Telepaque. . .


 

References

Next Article: